Most on here don't understand that it was univariate analysis, one indicator. In my opinion, they should not present univariate data. It just confuses shareholders and gives shorts a chance to manipulate. Multivariate analysis will produce data higher than V1 based off of the univariate data presented, which was super compelling. GC will not come out and say that the upcoming data will be higher. He just won't do that until he PR's it.

Again, I don't think they should have presented univariate data. But they did. I suppose they did it for the scientific community to build the case for cell cycle dysregulation. GC could have included one paragraph in that blog he did before AAIC and the communication before Summit. He could have explained the difference between univariate and multivariate analysis and state they are presenting univariate. He could have said univariate produces numbers that are much smaller (explain why) and expect those numbers to rise significantly (explain why). Simple. Not hard.

Lastly, huge positive last week. The addition of IP for Alzheimer's treatment makes the Dx/Tx 'portfolio' very attractive to potential partners. That is where I think this lands.